Literature DB >> 7937554

Disposition of azole antifungal agents. II. Hepatic binding and clearance of dichlorophenyl-bis-triazolylpropanol (DTP) in the rat.

H L Bomont1, M H Tarbit, M J Humphrey, J B Houston.   

Abstract

DTP (dichlorophenyl-bis-triazolylpropanol) was evaluated as a probe of drug-cytochromes P450 interactions in vitro and in vivo. Studies with rat liver microsomes demonstrate that DTP shows similar P450 binding affinity to its analog, ketoconazole, as determined by P450 difference spectra and inhibition of the metabolism of methoxycoumarin. As a more polar azole, DTP shows less affinity for rat plasma albumin (fraction unbound 0.56) than ketoconazole (fraction unbound 0.037). DTP metabolism is simpler than that of ketoconazole, with only one pathway, N-dealkylation which removes a triazole ring to yield DTP glycol. This primary metabolite is further metabolised to a carboxylic acid, a glycol glucuronide and a third unknown secondary metabolite (probably an acid glucuronide). Over a dose range of 0.1-24mg/kg there is complete mass balance recovery in urine via the five metabolites and unchanged drug. However DTP metabolism is dose dependent and while the affinity of DTP for the cytochromes P450 carrying out the initial dealkylation is high (1.5 microM based on unbound blood concentration), the capacity of the reaction is low (1 nmole/min). Under linear conditions, metabolic clearance is low (19ml/h), but ten-fold higher than renal clearance. The liver is the major distribution site for both DTP and ketoconazole. At low DTP concentrations, a specific high affinity process dominates the hepatic binding of DTP resulting in a liver:blood partition coefficient of approximately 30. Hepatic binding is concentration dependent and the progressive decrease in partition coefficient observed as the dose of DTP is escalated is coincident with a decrease in volume of distribution. The two saturable processes involved in the disposition of DTP result in an unusual concentration dependency in the blood concentration-time profile of this azole. Following administration of a high dose (10mg/kg) of DTP the log concentration-time profile is sigmoidal. At high concentrations (above 1mg/L) both the N-dealkylation and the hepatic binding of DTP are saturated, but as concentrations fall to approximately 0.05mg/L the former process becomes linear and the time profile is convex over this concentration range. At later times as DTP concentrations decline further, the tissue binding also reaches the linear region and the time profile becomes concave. Only at low concentrations (below 0.05mg/L) do both processes become first order and the true half life is evident.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937554     DOI: 10.1023/a:1018966800208

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins.

Authors:  A D Rodrigues; G G Gibson; C Ioannides; D V Parke
Journal:  Biochem Pharmacol       Date:  1987-12-15       Impact factor: 5.858

2.  Dose-dependent metabolism and hepatic distribution of phenprocoumon in rats.

Authors:  D Trenk; B Winkelmann; E Jähnchen; S Oie
Journal:  J Pharmacokinet Biopharm       Date:  1988-02

Review 3.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

4.  Linear and nonlinear kinetics of drug elimination. I. Kinetics on the basis of a single capacity-limited pathway of elimination with or without simultaneous supply-limited elimination.

Authors:  C A van Ginneken; J M van Rossum; H L Fleuren
Journal:  J Pharmacokinet Biopharm       Date:  1974-10

5.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

6.  Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.

Authors:  D R Kirsch; M H Lai; J O'Sullivan
Journal:  Gene       Date:  1988-09-07       Impact factor: 3.688

7.  Direct fluorometric methods for measuring mixed function oxidase activity.

Authors:  R A Prough; M D Burke; R T Mayer
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

8.  Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics.

Authors:  M Pasanen; T Taskinen; M Iscan; E A Sotaniemi; M Kairaluoma; O Pelkonen
Journal:  Biochem Pharmacol       Date:  1988-10-15       Impact factor: 5.858

9.  Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver.

Authors:  J J Sheets; J I Mason
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

10.  The disposition and pharmacokinetics of ketoconazole in the rat.

Authors:  R P Remmel; K Amoh; M M Abdel-Monem
Journal:  Drug Metab Dispos       Date:  1987 Nov-Dec       Impact factor: 3.922

View more
  2 in total

1.  Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes.

Authors:  H Yin; M W Anders; K R Korzekwa; L Higgins; K E Thummel; E D Kharasch; J P Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

2.  Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver.

Authors:  C M Ervine; J B Houston
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.